Medis Pharma Lithuania, UAB - financials and debts

Company age: 6 y. 9 mo.

Update

Medis Pharma Lithuania - Company finances

EUR
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 182,244 294,568 657,529 970,032 920,820 1,309,030
Profit before tax - - - - - -
Net profit 4,319 6,913 14,338 18,673 20,121 38,651
Equity 6,819 13,732 28,070 46,743 66,864 105,516
Liabilities 42,246 31,147 45,423 81,589 66,384 57,102
Non-current assets 3,126 3,459 8,490 8,499 11,149 9,992
Current assets 46,374 43,503 80,460 124,279 133,009 169,264
Total assets 49,500 46,962 88,950 132,778 144,158 179,256
Taxes paid
STI taxes - - - 51,088 63,404 71,648
Social insurance contributions - - - 98,290 95,116 119,152
Financial indicators
Revenue change y/y - +61.6% +123.2% +47.5% -5.1% +42.2%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 8.7% 14.7% 16.1% 14.1% 14.0% 21.6%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 63.3% 50.3% 51.1% 39.9% 30.1% 36.6%
Profit margin Net profit margin. Shows the overall profitability of the company. 2.4% 2.3% 2.2% 1.9% 2.2% 3.0%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. - - - - - -
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 6.2 2.3 1.6 1.7 1.0 0.5
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 95,082 126,245 121,389 129,338 116,314 148,193

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Medis Pharma Lithuania - Social security debts

From To Debt, €
2026-05-17 2026-05-17 569.35
2026-01-18 2026-01-18 309.47
2025-12-16 2025-12-16 590.85
2025-11-18 2025-12-04 55.84
2025-10-23 2025-11-04 0.31
2025-10-17 2025-10-19 125.78
2025-09-16 2025-09-25 7.77
2025-08-31 2025-09-03 7.77
2025-08-19 2025-08-29 7.77
2025-07-28 2025-08-04 7.77
2025-07-26 2025-07-27 7.07
2025-07-24 2025-07-25 7.77
2025-07-16 2025-07-23 7.07
2025-06-24 2025-07-03 7.07
2025-06-19 2025-06-23 195.99
2025-06-17 2025-06-18 7.08
2025-05-20 2025-05-27 50.95
2025-04-30 2025-04-30 0.52
2025-04-23 2025-04-27 145.65
2025-04-16 2025-04-22 0.52
2025-03-18 2025-04-03 0.52
2025-02-18 2025-03-04 0.52
2025-02-10 2025-02-10 0.52
2025-01-22 2025-02-04 0.52
2024-11-21 2024-12-01 2.06
2024-11-19 2024-11-20 214.45
2024-11-18 2024-11-18 2.06
2024-10-16 2024-11-05 2.06
2024-02-29 2024-03-04 82.01
2023-03-22 2023-03-29 21.23
2022-12-16 2023-01-04 0.22
2022-11-21 2022-12-04 0.22
2022-11-17 2022-11-18 0.22
2022-10-28 2022-11-03 0.22
2022-09-29 2022-10-02 72.45
2022-09-16 2022-09-28 4.72
2022-08-23 2022-09-04 4.72
2022-08-03 2022-08-04 70.77
2022-07-25 2022-08-02 4.72
2022-07-18 2022-07-24 3.05
2022-06-16 2022-07-04 3.05
2022-05-31 2022-06-05 216.12
2022-05-27 2022-05-30 97.38
2022-05-26 2022-05-26 3.05
2022-02-21 2022-02-24 1.22

Medis Pharma Lithuania - VMI tax arrears

The company had no tax arrears (debts) to the State Tax Inspectorate

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Medis Pharma Lithuania, UAB (code 305405895) is a Private Limited Liability Company engaged in business and other management consultancy activities. In 2025, the company generated revenue of €1.31 million and net profit of €38.7 thousand, with a profit margin of 3.0%. Revenue increased by 42.2% year on year and by 35.0% over two years, showing a clear upward trend after €970.0 thousand in 2023 and €920.8 thousand in 2024. Net profit also improved from €18.7 thousand in 2023 to €20.1 thousand in 2024 and €38.7 thousand in 2025. At the end of 2025, total assets amounted to €179.3 thousand, equity to €105.5 thousand and liabilities to €57.1 thousand. The equity ratio stood at 58.9% and debt-to-equity at 0.54, indicating a relatively conservative balance sheet structure. Asset turnover was 7.30x, ROE was 36.6% and ROA was 21.6%. With revenue per employee of €163.6 thousand and profit per employee of €4.8 thousand, the business showed solid operating efficiency in 2025.